2012
DOI: 10.1590/s1984-82502012000400005 View full text |Buy / Rent full text
|
|

Abstract: The present study was undertaken to develop sustained release (SR) matrix tablets of losartan potassium, an angiotensin-II antagonist for the treatment of hypertension. The tablets were prepared by direct compression method, along with Kollidon SR as release retardant polymer. The amount of losartan potassium remains fixed (100 mg) for all the three formulations whereas the amounts of Kollidon SR were 250 mg, 225 mg, and 200 mg for F-1, F-2, and F-3 respectively. The evaluation involves three stages: the micro… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
2
5
0

Publication Types

Select...

Relationship

0
0

Authors

Journals